Scientific technology for gene therapy has made tremendous progress and the regulatory landscape is still developing. Both the FDA and EMA have issued recommendations for gene therapies. Panelists will discuss recent updates to the policy landscape for in vivo and ex vivo gene therapy as well as opportunities for harmonization.
Ability Level: Intermediate
Session ID: 503767